/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results.
/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European.
SAN DIEGO, Feb. 6, 2023 /PRNewswire/ Halozyme Therapeutics, Inc. today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan brings more than 25 years of experience. | February 6, 2023
/PRNewswire/ Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March 17, 2023 (the "Redemption Date").